Global /United States /Healthcare /Medical Devices /TMDX
chevron_leftBack
TransMedics Group, Inc. logo

TransMedics Group, Inc.

TMDX
NASDAQ: TMDX Delayed
98.57USD -2.7%
As of 13 June 2026, TransMedics Group, Inc. has a market cap of $3.41B USD, ranking #4985 globally and #1362 in the United States. It ranks #386 in the Healthcare sector, and #86 in the Medical Devices industry.
Global Rank
4985
Country Rank
1362
Sector Rank
386
Industry Rank
86
Key Stats
Market Cap
$3.41BUSD
Enterprise Value
$3.44BUSD
Revenue (TTM)
$605.49MUSD
EBITDA (TTM)
$134.47MUSD
Net Income (TTM)
$190.29MUSD
EBITDA Margin
22%
Profit Margin
31%
PE Ratio
20.2
Forward PE
40.1
PS Ratio
5.6
PB Ratio
7.1
EV/EBITDA
25.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Waleed Hassanein open_in_new
Employees
898
Founded
1998
IPO
02 May 2019
Website
transmedics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.7% -14% -0.5% -30% -24% 9.3%

News

Loading...

TMDX Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
TMDX
TransMedics Group Inc
ISIN: US89377M1099
Shares Out.:
34.561M1 Shares Float: 33.375M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
98.57 USD
Borsa Italiana
MIC: XMIL
1TMDX
TransMedics Group Inc
ISIN: US89377M1099
TV:
SA:
YF:
GF:
BA:
MS:
86.48 EUR
Frankfurt Stock Exchange
MIC: XFRA
8T8
TransMedics Group Inc
ISIN: US89377M1099
TV:
SA:
YF:
GF:
BA:
8T8
MS:
63.76 EUR
Show all 4 markets
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About TransMedics Group, Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Similar Companies

Industry: Medical Devices (United States)
Name
Market Cap diff.
PE
$173.27B
5K%
25.8
$160.73B
5K%
56.7
$159.07B
5K%
25.6
DHR
$126.55B
4K%
34.7
SYK
$120.69B
3K%
38.3
$84.93B
2K%
24.5
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
MDT
$101.9B
3K%
22.2
$97.46B
84.32B EUR
3K%
36.7
7741
$61.41B
9.83T JPY
2K%
40.0
$45.47B
39.34B EUR
1K%
18.7
ALC
$36.38B
28.99B CHF
968%
37.9
$30.06B
203.66B CNY
783%
26.0
chevron_leftBack